70 related articles for article (PubMed ID: 7991156)
1. [Clinical considerations in Raynaud's phenomenon. How many and which patients are treated?].
Gallo E; Bianchi E; Motta A; Carugati C
Minerva Cardioangiol; 1994 Sep; 42(9):379-85. PubMed ID: 7991156
[TBL] [Abstract][Full Text] [Related]
2. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
3. [Video-thoracoscopic sympathectomy in the treatment of Raynaud's disease and palmar hyperhidrosis].
Trignano M; Boatto R; Mastino GP; Ferrandu T; Padula G; Loi V; Pala C
Minerva Chir; 2000; 55(1-2):17-23. PubMed ID: 10832279
[TBL] [Abstract][Full Text] [Related]
4. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
5. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
Rychlik-Golema W; Mastej K; Adamiec R
Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
[TBL] [Abstract][Full Text] [Related]
6. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
7. Need to expand microvascular investigation of patients with Raynaud's phenomenon of different etiology: clinical patterns of 106 consecutive patients.
Arpaia G; Cimminiello C; Bellone M; Aloisio M; Rossi F; Bonfardeci G
Int Angiol; 1994 Mar; 13(1):15-8. PubMed ID: 8077792
[TBL] [Abstract][Full Text] [Related]
8. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance.
Hirschl M; Hirschl K; Lenz M; Katzenschlager R; Hutter HP; Kundi M
Arthritis Rheum; 2006 Jun; 54(6):1974-81. PubMed ID: 16732585
[TBL] [Abstract][Full Text] [Related]
9. Raynaud's phenomenon.
O'connor CM
J Vasc Nurs; 2001 Sep; 19(3):87-92; quiz 93-4. PubMed ID: 11533581
[TBL] [Abstract][Full Text] [Related]
10. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
11. Raynaud's phenomenon: clinical spectrum of 118 patients.
De Angelis R; Del Medico P; Blasetti P; Cervini C
Clin Rheumatol; 2003 Oct; 22(4-5):279-84. PubMed ID: 14576990
[TBL] [Abstract][Full Text] [Related]
12. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
[TBL] [Abstract][Full Text] [Related]
13. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison.
Maricq HR; Carpentier PH; Weinrich MC; Keil JE; Palesch Y; Biro C; Vionnet-Fuasset M; Jiguet M; Valter I
J Rheumatol; 1997 May; 24(5):879-89. PubMed ID: 9150076
[TBL] [Abstract][Full Text] [Related]
14. Thermographic parameters in the diagnosis of secondary Raynaud's phenomenon.
Schuhfried O; Vacariu G; Lang T; Korpan M; Kiener HP; Fialka-Moser V
Arch Phys Med Rehabil; 2000 Apr; 81(4):495-9. PubMed ID: 10768542
[TBL] [Abstract][Full Text] [Related]
15. [The incidence of Raynaud's phenomenon in 1920 residents in Milan].
Gallo E; Bianchi E; Motta A; Piccolo N
Minerva Cardioangiol; 1994; 42(1-2):65-71. PubMed ID: 8022547
[TBL] [Abstract][Full Text] [Related]
16. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM
Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104
[TBL] [Abstract][Full Text] [Related]
17. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
Haynes DS; O'Malley M; Cohen S; Watford K; Labadie RF
Laryngoscope; 2007 Jan; 117(1):3-15. PubMed ID: 17202923
[TBL] [Abstract][Full Text] [Related]
18. The incidence and natural history of Raynaud's phenomenon in the community.
Suter LG; Murabito JM; Felson DT; Fraenkel L
Arthritis Rheum; 2005 Apr; 52(4):1259-63. PubMed ID: 15818710
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
20. Raynaud's phenomenon. A practical approach to a common problem.
Needs J; Laurent R; Manolios N
Aust Fam Physician; 1993 Jun; 22(6):1049, 1052-8, 1062-5. PubMed ID: 8338452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
